/

RPRX

Royalty Pharma plcOpen

56.94−0.84 −1.45%USD

NasdaqGS · as of Oct 13, 11:21 ET · 15m delay

Open

57.80

Prev close

57.78

Day range

56.8057.97

52-week range

35.5064.38

Volume

1.43M0.49×

Mkt cap

32.90B

P/E ttm

30.29

Fwd P/E

9.82

EPS ttm

1.88

Div yield

1.63%

Earnings

Nov 4, 2026

From 52w high

−11.56%

Price Chart

Yahoo Finance · delayed

RPRXOct 13, 2026O 57.80H 57.97L 56.80C 56.94−0.84 (−1.45%)Vol 1.43M

SMA 5059.15
SMA 20051.71

1Y change +58.12% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

RPRX Royalty Pharma plc · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +0.89%
1 month: −2.85%
3 months: +2.28%
6 months: +16.63%
Year to date: +47.36%
1 year: +60.67%

Valuation & ownership

Market cap: 32.90B
Enterprise value: 36.81B
P/E (ttm): 30.29
Forward P/E: 9.82
PEG ratio: 1.33
Price / book: 3.71
Price / sales (ttm): 12.97
EV / EBITDA: 23.63
EPS (ttm): 1.88
EPS (forward): 5.80
Beta (5y monthly): 0.41
Dividend yield: 1.63%
Payout ratio: 48.40%
Shares outstanding: 445.28M
Float: 417.58M
Short % of float: 2.93%
Short ratio (days): 3.89
Held by insiders: 6.49%
Held by institutions: 87.67%
Avg volume (3m): 2.93M
50-day average: 59.15
200-day average: 51.63
52-week change: +60.67%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 42.1
vs 50-day SMA: −3.73%
vs 200-day SMA: +10.11%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 2.16%
Realised vol (20d, ann.): 14.2%
From 52-week high: −11.56%
From 52-week low: +60.40%

ANR

Analyst Consensus

8 analysts

Consensus

Strong buy

1.50 on a 1 (strong buy) – 5 (sell) scale

Mean target

65.38

+14.81% implied

Low 61.00Median 66.00High 70.00

Recommendation trend

Now7 / 1 / 0
1m ago7 / 1 / 0

DES

About Royalty Pharma plc

Yahoo Finance profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.

Sector: Healthcare
Industry: Biotechnology
Employees: 100
Headquarters: New York, NY, United States
Website: royaltypharma.com
Officers: Mr. Pablo Legorreta Founder, Chairman of the Board & CEO
Mr. Terrance P. Coyne Executive VP & CFO
Mr. Christopher Hite Chairman of Partnering & Investments
Dr. Marshall Jonathan Urist M.D., Ph.D. Head of Research & Investments

SEAS

Seasonality · RPRX

2020–2026 · monthly returns

Strongest month Nov +4.45%Weakest month May −3.98%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	7.9	10.9	3.8	4.4	11.3	0.6	4.2	5.1	-5.0	-2.4			+47.4%
2025	23.8	6.5	-7.5	5.4	0.2	9.6	2.1	-2.2	-1.9	6.4	6.6	-3.4	+51.5%
2024	1.1	6.9	0.1	-8.8	-1.0	-3.8	6.8	3.1	-2.5	-4.6	-1.3	-4.3	−9.2%
2023	-0.8	-8.5	0.5	-2.4	-6.9	-6.1	2.1	-5.0	-9.0	-1.0	0.7	3.8	−28.9%
2022	0.4	-1.9	-0.8	9.3	-3.4	2.2	3.4	-3.9	-3.9	5.3	3.9	-10.1	−0.8%
2021	-6.1	-0.9	-6.3	0.9	-8.8	2.2	-6.8	1.2	-6.5	9.4	0.6	0.2	−20.4%
2020							-11.3	-3.9	1.7	-12.8	16.1	17.5	+3.1%

INSD

Insider Activity · RPRX

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

360.5K shares

Sells, 6 months

647.1K shares

Net shares

−286.5K

Net change in insider shares

−1.00%

Date	Insider	Transaction	Shares	Value
Oct 4, 2026	Urist Marshall J.Officer	Sale at price 57.10 per share.	4.1K	$235.59K
Sep 29, 2026	Bassler Bonnie LDirector	Stock Award(Grant) at price 58.41 per share.	642	$37.50K
Sep 27, 2026	Urist Marshall J.Officer	Sale at price 57.88 per share.	4.1K	$238.81K
Sep 21, 2026	Hite ChristopherOfficer	Sale at price 58.51 - 58.93 per share.	100K	$5.85M
Aug 18, 2026	Hite ChristopherOfficer	Stock Gift at price 0.00 per share.	16.8K	—
Aug 17, 2026	Hite ChristopherOfficer	Sale at price 59.97 per share.	100K	$6.00M
Aug 12, 2026	Coyne Terrance PChief Financial Officer	Sale at price 58.59 - 59.14 per share.	11K	$645.55K
Aug 4, 2026	Legorreta Pablo GChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	65.2K	—
Aug 4, 2026	Hite ChristopherOfficer	Stock Award(Grant) at price 0.00 per share.	11K	—
Aug 4, 2026	Coyne Terrance PChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	11K	—
Aug 4, 2026	Urist Marshall J.Officer	Stock Award(Grant) at price 0.00 per share.	8.3K	—
Jun 30, 2026	Urist Marshall J.Officer	Sale at price 55.88 per share.	9.1K	$508.45K
Jun 29, 2026	Bassler Bonnie LDirector	Stock Award(Grant) at price 54.40 per share.	689	$37.48K
Jun 29, 2026	Hite ChristopherOfficer	Sale at price 56.44 - 57.10 per share.	130K	$7.35M
Jun 23, 2026	Urist Marshall J.Officer	Sale at price 55.18 per share.	9.1K	$502.07K
Jun 22, 2026	Hite ChristopherOfficer	Sale at price 54.11 - 54.47 per share.	150K	$8.16M
Jun 4, 2026	Hodgson David CDirector	Stock Award(Grant) at price 0.00 per share.	4.5K	—
Jun 4, 2026	Weatherman Elizabeth HDirector	Stock Award(Grant) at price 0.00 per share.	4.5K	—
Jun 4, 2026	Norden GregoryDirector	Stock Award(Grant) at price 0.00 per share.	4.5K	—
Jun 4, 2026	Bassler Bonnie LDirector	Stock Award(Grant) at price 0.00 per share.	4.5K	—

13F

Investors Holding RPRX

latest 13F filings of 29 followed managers

Investors holding RPRX
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$108.5M	0.15%	1.94M	+145%	Q2 2026
Bridgewater Associates · Ray Dalio	$12.3M	0.05%	219.69K	New	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

RPRX

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

RPRX

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Royalty Pharma plc

Seasonality · RPRX

Insider Activity · RPRX

Congress Trades · RPRX

Investors Holding RPRX

Investors Holding RPRX

Congress Trades · RPRX

Insider Activity · RPRX

Seasonality · RPRX

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Royalty Pharma plc

Financial Snapshot

Earnings & Dividends

News